Your browser is no longer supported. Please, upgrade your browser.
Settings
ADPT Adaptive Biotechnologies Corporation daily Stock Chart
ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-0.66 Insider Own1.40% Shs Outstand126.06M Perf Week-8.60%
Market Cap5.16B Forward P/E- EPS next Y-1.09 Insider Trans-65.50% Shs Float76.08M Perf Month-16.75%
Income-82.30M PEG- EPS next Q-0.29 Inst Own74.40% Short Float3.22% Perf Quarter-3.36%
Sales93.30M P/S55.34 EPS this Y-42.00% Inst Trans2.51% Short Ratio2.11 Perf Half Y16.95%
Book/sh4.38 P/B8.40 EPS next Y-4.80% ROA-10.00% Target Price52.25 Perf Year-12.45%
Cash/sh3.96 P/C9.30 EPS next 5Y10.00% ROE-23.10% 52W Range15.19 - 55.12 Perf YTD22.93%
Dividend- P/FCF- EPS past 5Y- ROI-12.90% 52W High-30.48% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin75.70% 52W Low152.27% ATR2.02
Employees453 Current Ratio7.50 Sales Q/Q64.60% Oper. Margin-99.60% RSI (14)43.83 Volatility5.41% 4.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-58.30% Profit Margin-88.20% Rel Volume0.43 Prev Close36.78
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume1.16M Price38.32
Recom1.50 SMA20-1.14% SMA50-9.14% SMA20017.21% Volume372,340 Change4.19%
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Aug-11-20 01:01AM  
Aug-10-20 06:35PM  
04:05PM  
12:44PM  
08:05AM  
Aug-06-20 09:24AM  
Aug-04-20 09:30AM  
Jul-30-20 06:19AM  
Jul-28-20 06:04PM  
Jul-16-20 12:00PM  
Jul-15-20 07:47PM  
Jul-14-20 04:44PM  
Jul-09-20 04:29PM  
08:05AM  
Jun-23-20 11:54AM  
Jun-17-20 08:56AM  
Jun-15-20 10:27AM  
Jun-11-20 09:00AM  
Jun-08-20 04:03PM  
Jun-07-20 06:25AM  
May-27-20 04:03PM  
May-19-20 08:03AM  
May-18-20 02:47PM  
May-14-20 11:51AM  
May-13-20 12:31PM  
07:02AM  
May-12-20 04:03PM  
08:06AM  
May-11-20 10:57AM  
09:57AM  
May-08-20 09:09AM  
May-06-20 03:06PM  
02:50PM  
12:10PM  
08:19AM  
08:00AM  
May-05-20 12:00PM  
Apr-30-20 08:51AM  
06:39AM  
Apr-27-20 04:03PM  
Apr-20-20 08:15AM  
Apr-17-20 09:13PM  
12:40PM  
Apr-15-20 04:47PM  
08:26AM  
Apr-09-20 07:45PM  
Apr-07-20 08:35PM  
Apr-05-20 10:14AM  
Apr-03-20 10:51AM  
Apr-02-20 07:58PM  
05:50PM  
04:23PM  
04:04PM  
12:29PM  
09:34AM  
09:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:45PM  
Mar-23-20 11:06AM  
Mar-20-20 02:00PM  
01:02PM  
Feb-29-20 07:12AM  
Feb-27-20 05:54PM  
Feb-26-20 04:05PM  
Feb-21-20 10:20AM  
Feb-19-20 04:05PM  
Feb-12-20 04:05PM  
Feb-10-20 08:44AM  
Feb-03-20 11:27AM  
Jan-31-20 11:52AM  
Jan-29-20 09:50AM  
Jan-23-20 08:53PM  
Jan-22-20 08:25AM  
Jan-21-20 04:39PM  
04:02PM  
Jan-13-20 07:30AM  
Jan-08-20 07:30AM  
Dec-30-19 04:05PM  
10:04AM  
Dec-26-19 02:47PM  
Dec-20-19 04:17PM  
Dec-16-19 09:24PM  
Dec-13-19 04:52AM  
Dec-09-19 08:44AM  
08:00AM  
Dec-04-19 04:30PM  
Dec-03-19 04:34PM  
Nov-22-19 03:01AM  
Nov-19-19 12:26PM  
Nov-12-19 04:05PM  
Nov-11-19 09:28AM  
Oct-29-19 04:05PM  
Oct-14-19 06:43PM  
Oct-09-19 08:37AM  
Sep-26-19 07:13AM  
Sep-25-19 08:44AM  
Sep-24-19 08:00AM  
Sep-17-19 08:00AM  
Sep-08-19 07:45PM  
Aug-16-19 04:22PM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALDO LANCEChief Medical OfficerAug 06Option Exercise7.806,25048,7506,250Aug 07 08:00 PM
BALDO LANCEChief Medical OfficerAug 06Sale40.006,250250,0000Aug 07 08:00 PM
BENZENO SHARONChief Business Development OffAug 04Option Exercise6.697,18748,1047,187Aug 05 09:00 PM
BENZENO SHARONChief Business Development OffAug 04Sale40.007,187287,4800Aug 05 09:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaAug 03Option Exercise0.841,6001,34411,600Aug 05 09:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaAug 03Sale37.371,60059,79210,000Aug 05 09:00 PM
ROBINS CHAD MCEO and ChairmanJul 31Option Exercise0.3316,6805,5041,794,860Jul 31 09:05 PM
ROBINS CHAD MCEO and ChairmanJul 31Sale37.2316,680621,0491,778,180Jul 31 09:05 PM
ROBINS CHAD MCEO and ChairmanJul 30Option Exercise0.3316,6805,5041,794,860Jul 31 09:05 PM
ROBINS CHAD MCEO and ChairmanJul 30Sale37.7616,680629,9111,778,180Jul 31 09:05 PM
ROBINS CHAD MCEO and ChairmanJul 29Option Exercise0.3320,6686,8201,798,848Jul 31 09:05 PM
ROBINS CHAD MCEO and ChairmanJul 29Sale38.1420,668788,2781,778,180Jul 31 09:05 PM
Taylor Stacy LSVP and General CounselJul 24Option Exercise7.032,88020,2504,180Jul 24 09:00 PM
Taylor Stacy LSVP and General CounselJul 24Sale36.032,880103,7661,300Jul 24 09:00 PM
BENZENO SHARONChief Business Development OffJul 20Option Exercise6.274172,615417Jul 21 08:47 AM
GOEL DAVID E.DirectorJul 20Sale40.002,000,00080,000,00013,115,090Jul 22 04:15 PM
BENZENO SHARONChief Business Development OffJul 20Sale40.0041716,6800Jul 21 08:47 AM
ROBINS HARLAN SChief Scientific OfficerJul 17Option Exercise6.3211,10070,15211,779Jul 17 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 17Sale39.6011,100439,611679Jul 17 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 16Option Exercise6.3222,200140,30422,879Jul 17 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 16Sale39.5722,200878,369679Jul 17 09:00 PM
LO FRANCISChief People OfficerJul 15Option Exercise7.802,00015,6002,000Jul 17 09:00 PM
HERSHBERG ROBERTDirectorJul 15Option Exercise0.452,0009002,000Jul 17 09:00 PM
HERSHBERG ROBERTDirectorJul 15Sale43.852,00087,6900Jul 17 09:00 PM
LO FRANCISChief People OfficerJul 15Sale43.862,00087,7100Jul 17 09:00 PM
RUBINSTEIN JULIEPresidentJul 09Option Exercise0.8415,27512,83115,275Jul 10 08:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJul 09Option Exercise0.8417,40014,61627,400Jul 10 08:00 PM
RUBINSTEIN JULIEPresidentJul 09Sale49.0015,275748,4750Jul 10 08:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJul 09Sale49.0017,400852,60010,000Jul 10 08:00 PM
Cohen Chad MChief Financial OfficerJul 08Option Exercise6.3230,000189,60031,000Jul 10 08:00 PM
Cohen Chad MChief Financial OfficerJul 08Sale46.8730,0001,406,0731,000Jul 10 08:00 PM
BALDO LANCEChief Medical OfficerJul 06Option Exercise7.806,25048,7506,250Jul 08 08:10 PM
DOBMEIER ERICDirectorJul 06Option Exercise6.3210,00063,20010,000Jul 08 08:28 PM
BALDO LANCEChief Medical OfficerJul 06Sale47.336,250295,7890Jul 08 08:10 PM
DOBMEIER ERICDirectorJul 06Sale47.3710,000473,6560Jul 08 08:28 PM
BENZENO SHARONChief Business Development OffJul 01Option Exercise6.726,77145,4756,771Jul 02 07:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJul 01Option Exercise0.843,0002,52013,000Jul 02 07:00 PM
BENZENO SHARONChief Business Development OffJul 01Sale47.346,771320,5400Jul 02 07:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJul 01Sale47.423,000142,26610,000Jul 02 07:00 PM
BENZENO SHARONChief Business Development OffJun 26Option Exercise6.324172,635417Jun 30 08:25 PM
BENZENO SHARONChief Business Development OffJun 26Option Exercise6.324172,635417Jul 01 09:55 AM
BENZENO SHARONChief Business Development OffJun 26Sale47.4241719,7740Jun 30 08:25 PM
BENZENO SHARONChief Business Development OffJun 26Sale47.4241719,7740Jul 01 09:55 AM
ROBINS HARLAN SChief Scientific OfficerJun 25Option Exercise6.3211,10070,15211,779Jun 25 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJun 25Sale46.8811,100520,423679Jun 25 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJun 24Option Exercise6.3211,10070,15211,779Jun 25 08:00 PM
Taylor Stacy LSVP and General CounselJun 24Option Exercise7.032,88020,2504,180Jun 25 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJun 24Sale45.8911,100509,355679Jun 25 08:00 PM
Taylor Stacy LSVP and General CounselJun 24Sale46.682,880134,4381,300Jun 25 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJun 23Option Exercise6.3211,10070,15211,779Jun 25 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJun 23Sale46.8511,100520,035679Jun 25 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 22Option Exercise0.3333,13210,9341,811,312Jun 23 08:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJun 22Option Exercise0.8419,00015,96029,000Jun 23 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 22Sale45.8533,1321,519,2271,778,180Jun 23 08:00 PM
HILL NANCY LOUISEEVP, Operations & Program ManaJun 22Sale45.2219,000859,12010,000Jun 23 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 19Option Exercise0.3324,5608,1051,802,740Jun 19 08:00 PM
BENZENO SHARONChief Business Development OffJun 19Option Exercise6.274172,615417Jun 23 08:00 PM
BENZENO SHARONChief Business Development OffJun 19Sale45.0041718,7650Jun 23 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 19Sale44.9224,5601,103,2341,778,180Jun 19 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 18Option Exercise0.3316,6805,5041,794,860Jun 19 08:00 PM
LO FRANCISChief People OfficerJun 18Option Exercise7.802,00015,6002,000Jun 19 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 18Sale44.4116,680740,7591,778,180Jun 19 08:00 PM
LO FRANCISChief People OfficerJun 18Sale44.342,00088,6800Jun 19 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 17Option Exercise0.3328,4409,3851,806,620Jun 19 08:00 PM
ROBINS CHAD MCEO and ChairmanJun 17Sale44.3728,4401,261,9191,778,180Jun 19 08:00 PM
HERSHBERG ROBERTDirectorJun 15Option Exercise0.452,0009002,000Jun 17 08:00 PM
HERSHBERG ROBERTDirectorJun 15Sale43.002,00085,9970Jun 17 08:00 PM
BALDO LANCEChief Medical OfficerJun 09Option Exercise7.804,16732,5034,167Jun 10 08:00 PM
Cohen Chad MChief Financial OfficerJun 09Option Exercise6.328,75055,3009,750Jun 10 08:00 PM
BALDO LANCEChief Medical OfficerJun 09Sale40.004,167166,6800Jun 10 08:00 PM
Cohen Chad MChief Financial OfficerJun 09Sale40.008,750350,0001,000Jun 10 08:00 PM
BALDO LANCEChief Medical OfficerJun 08Option Exercise7.802,08316,2472,083Jun 10 08:00 PM
Cohen Chad MChief Financial OfficerJun 08Option Exercise6.3221,250134,30022,250Jun 10 08:00 PM
BALDO LANCEChief Medical OfficerJun 08Sale39.022,08381,2880Jun 10 08:00 PM
Cohen Chad MChief Financial OfficerJun 08Sale39.0821,250830,5181,000Jun 10 08:00 PM
DOBMEIER ERICDirectorJun 03Option Exercise6.325,00031,6005,000Jun 05 08:00 PM
BENZENO SHARONChief Business Development OffJun 03Option Exercise6.726,77045,4686,770Jun 05 08:00 PM
DOBMEIER ERICDirectorJun 03Sale39.795,000198,9500Jun 05 08:00 PM
BENZENO SHARONChief Business Development OffJun 03Sale40.006,770270,8000Jun 05 08:00 PM
Taylor Stacy LSVP and General CounselMay 26Option Exercise7.032,88020,2504,180May 28 09:00 PM
BENZENO SHARONChief Business Development OffMay 26Option Exercise6.324162,629416May 28 09:00 PM
Taylor Stacy LSVP and General CounselMay 26Sale42.002,880120,9601,300May 28 09:00 PM
BENZENO SHARONChief Business Development OffMay 26Sale42.0041617,4720May 28 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 21Option Exercise0.3350,00016,5001,928,180May 21 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 21Sale40.2950,0002,014,5001,878,180May 21 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 20Option Exercise0.3350,00016,5001,928,180May 21 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 20Sale40.4650,0002,023,0001,878,180May 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerMay 20Sale40.4831,3721,269,939679May 21 09:00 PM
DOBMEIER ERICDirectorMay 19Option Exercise6.325,00031,6005,000May 21 09:00 PM
Cohen Chad MChief Financial OfficerMay 19Option Exercise4.9750,000248,50051,000May 21 09:00 PM
BENZENO SHARONChief Business Development OffMay 19Option Exercise5.48246,7701,351,515246,770May 21 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 19Option Exercise0.3350,00016,5001,928,180May 21 09:00 PM
ROBINS CHAD MCEO and ChairmanMay 19Sale39.9450,0001,996,9241,878,180May 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerMay 19Sale40.1138,6281,549,36932,051May 21 09:00 PM
BENZENO SHARONChief Business Development OffMay 19Sale40.00246,7709,870,8000May 21 09:00 PM
Cohen Chad MChief Financial OfficerMay 19Sale40.0050,0002,000,0001,000May 21 09:00 PM
DOBMEIER ERICDirectorMay 19Sale40.005,000200,0000May 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerMay 18Option Exercise6.3211,10070,15281,779May 18 09:00 PM
ROBINS HARLAN SChief Scientific OfficerMay 18Sale39.3211,100436,48270,679May 18 09:00 PM
HERSHBERG ROBERTDirectorMay 15Option Exercise0.452,0009002,000May 18 09:00 PM